Autolus Therapeutics PLC
AUTL2.355USD
+0.005+0.21%
交易中 （美東）報價延遲15分鐘
626.73M總市值
虧損本益比TTM
關於 Autolus Therapeutics PLC 公司
Autolus Therapeutics plc 是一家英國臨牀階段生物製藥公司，致力於開發用於治療癌症和自身免疫性疾病的程序化 T 細胞療法。該公司專注於嵌合抗原受體 (CAR)-T 細胞療法。該公司利用一套專有和模塊化的 T 細胞編程技術，設計出有針對性的、可控的、高活性的 T 細胞療法候選產品，旨在識別靶細胞、破壞其防禦機制並消滅這些細胞。該公司擁有一系列用於治療血液系統惡性腫瘤、實體瘤和自身免疫性疾病的候選產品。其產品線包括 obe-cel (FELIX)、obe-cel (ALLCAR19)、obe-cel (CAROUSEL)、AUTO1/22 (CARPALL)、AUTO4 (LibrA T1)、AUTO6 (MAGNETO)、AUTO5、AUTO8 (MCARTY) 和 AUTO9。 AUTO4 和 AUTO5 是兩種程序化 T 細胞療法，用於治療針對 T 細胞受體β 常數 (TRBC) 1 和 TRBC 2 的外周 T 細胞淋巴瘤。
公司簡介
公司代碼AUTL
公司名稱Autolus Therapeutics PLC
上市日期Jun 22, 2018
CEODr. Christian Martin Itin, Ph.D.
員工數量647
證券類型Depository Receipt
年結日Jun 22
公司地址The Mediaworks
城市LONDON
上市交易所NASDAQ Global Select Consolidated
國家United Kingdom
郵編W12 7FP
電話442038296230
網址https://www.autolus.com/
公司代碼AUTL
上市日期Jun 22, 2018
CEODr. Christian Martin Itin, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. Robert (Rob) Dolski
Mr. Robert (Rob) Dolski
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chairman of the Board
Chairman of the Board
--
--
Mr. John Edward Berriman
Mr. John Edward Berriman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William D. (Bill) Young, Ph.D.
Mr. William D. (Bill) Young, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. Robert (Rob) Dolski
Mr. Robert (Rob) Dolski
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chairman of the Board
Chairman of the Board
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
暫無數據
地區USD
名稱
營收
佔比
United States
8.98M
100.00%
United Kingdom
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 6月27日 週五
更新時間: 6月27日 週五
持股股東
股東類型
持股股東
持股股東
佔比
BioNTech SE
12.52%
Syncona Investment Management Limited
11.55%
Wellington Management Company, LLP
10.18%
Clarus Ventures, LLC
7.70%
Deep Track Capital LP
6.71%
Other
51.34%
持股股東
持股股東
佔比
BioNTech SE
12.52%
Syncona Investment Management Limited
11.55%
Wellington Management Company, LLP
10.18%
Clarus Ventures, LLC
7.70%
Deep Track Capital LP
6.71%
Other
51.34%
股東類型
持股股東
佔比
Investment Advisor
30.97%
Hedge Fund
22.24%
Investment Advisor/Hedge Fund
21.92%
Corporation
12.52%
Venture Capital
7.96%
Sovereign Wealth Fund
5.64%
Holding Company
5.55%
Private Equity
1.74%
Research Firm
0.57%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
230
290.52M
109.16%
+36.32M
2025Q1
233
278.22M
104.55%
+21.95M
2024Q4
238
276.47M
103.89%
+17.40M
2024Q3
228
281.50M
105.79%
+29.96M
2024Q2
230
250.31M
94.10%
+23.29M
2024Q1
222
248.02M
93.27%
+78.60M
2023Q4
195
154.83M
95.00%
+7.81M
2023Q3
172
154.39M
98.35%
+17.90M
2023Q2
174
153.07M
97.70%
+21.18M
2023Q1
175
149.40M
95.88%
+11.90M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BioNTech SE
33.33M
12.52%
+33.33M
--
Feb 13, 2024
Syncona Investment Management Limited
30.73M
11.55%
+30.73M
--
Sep 30, 2024
Wellington Management Company, LLP
27.09M
10.18%
+1.75M
+6.89%
Mar 31, 2025
Clarus Ventures, LLC
20.49M
7.7%
--
--
Mar 31, 2025
Deep Track Capital LP
17.85M
6.71%
+3.63M
+25.53%
Mar 31, 2025
Syncona Portfolio Ltd
16.64M
6.25%
--
--
Mar 31, 2025
MAK Capital One, LLC
15.41M
5.79%
+15.41M
--
Jun 17, 2025
Qatar Investment Authority
15.00M
5.64%
--
--
Mar 01, 2025
PPF Group N.V.
14.78M
5.55%
+170.00K
+1.16%
Oct 24, 2024
Armistice Capital LLC
11.00M
4.13%
+1.80M
+19.57%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.95%
Invesco NASDAQ Future Gen 200 ETF
0.59%
ALPS Medical Breakthroughs ETF
0.41%
Tema Oncology ETF
0.31%
iShares Health Innovation Active ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.04%
SPDR S&P International Small Cap ETF
0.02%
Fidelity Fundamental Small-Mid Cap ETF
0%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.95%
Invesco NASDAQ Future Gen 200 ETF
佔比0.59%
ALPS Medical Breakthroughs ETF
佔比0.41%
Tema Oncology ETF
佔比0.31%
iShares Health Innovation Active ETF
佔比0.09%
ProShares Ultra Nasdaq Biotechnology
佔比0.05%
Invesco Nasdaq Biotechnology ETF
佔比0.05%
iShares Biotechnology ETF
佔比0.04%
SPDR S&P International Small Cap ETF
佔比0.02%
Fidelity Fundamental Small-Mid Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
